London-listed pharmaceutical giant GlaxoSmithKline(LSE: GSK) announced today that it has submitted a Biologics License Application (BLA) for its candidate shingles vaccine, Shingrix, to the United States Food and Drug Administration (FDA), seeking ...
GlaxoSmithKline plc logo GlaxoSmithKline plc (LON:GSK) had its price target raised by investment analysts at Credit Suisse Group AG from GBX 1,440 ($17.55) to GBX 1,800 ($21.94) in a note issued to investors on Friday.
GlaxoSmithKline plc's (GSK) witnessed a loss of -1.09% in recent trading period with closing price of $ 40.68. The company's last traded volume of 3.09 million shares as compared to it's an average volume of 2.68 million shares.
GlaxoSmithKline (NYSE:GSK) and Johnson & Johnson (NYSE:JNJ) are giants in their field, and they've both earned well-deserved reputations for taking advantage of opportunities in the pharmaceutical industry that have turned into sizable profits.